New and emerging indications of botulinum toxin therapy

Parkinsonism and Related Disorders

Volumn 17, Issue SUPPL. 1, 2011, Pages

  Kaji, Ryuji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

A1; A2; Botulinum toxin; Epilepsy; Pain; Spasticity; Therapy

Indexed keywords

BOTULINUM TOXIN; GLUTAMIC ACID;

ANALGESIA; ARTICLE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SYNTHESIS; DRUG USE; EPILEPSY; FUNCTIONAL STATUS; HEMIFACIAL SPASM; HUMAN; LIMB MOVEMENT; MIGRAINE; MUSCLE HYPERTONIA; NEUROTRANSMITTER RELEASE; NONHUMAN; OVERACTIVE BLADDER; PAIN; PRIORITY JOURNAL; SPASMODIC DYSPHONIA; SPASTICITY; URINARY URGENCY;

ANIMALS; BOTULINUM TOXINS; FORECASTING; HUMANS; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; PRESYNAPTIC TERMINALS; PROTEIN BINDING; SYNAPTIC TRANSMISSION;

EID: 80054095085     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.06.017     Document Type: Article

References (23)

1. Montecucco C., Schiavo G., Pantano S. SNARE complexes and neuroexocytosis: how many, how close?. Trends Biochem Sci 2005, 30:367-372.
2. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80:717-766.
3. Nishiki T., Kamata Y., Nemoto Y., Yoshida A., Sato K., Sekiguchi M., et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 1994, 269:10498-10503.
4. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
5. Kim H.S., Hwang J.H., Jeong S.T., Lee Y.T., Lee P.K., Suh Y.L., et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003, 45:200-206.
6. Fahrer J., Plunien R., Binder U., Langer T., Seliger H., Barth H. Genetically engineered clostridial C2 toxin as a novel delivery system for living mammalian cells. Bioconjug Chem 2010, 21:130-139.
7. Mezaki T., Kaji R., Brin M.F., Hirota-Katayama M., Kubori T., Shimizu T., et al. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial. Mov Disord 1999, 14:1017-1020.
8. Akaike N., Ito Y., Shin M.C., Nonaka K., Torii Y., Harakawa T., et al. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses. Toxicon 2010, 56:1315-1326.
9. Torii Y., Kiyota N., Sugimoto N., Mori Y., Goto Y., Harakawa T., et al. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 2011, 57:93-99.
10. Simpson D.M., Gracies J.M., Graham H.K., Miyasaki J.M., Naumann M., Russman B., et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2008, 70:1691-1698.
11. Simpson D.M., Alexander D.N., O'Brien C.F., Tagliati M., Aswad A.S., Leon J.M., et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306-1310.
12. Kaji R., Osako Y., Suyama K., Maeda T., Uechi Y., Iwasaki M. Botulinum toxin type A in post-strokeupper limb spasticity. Curr Med Res Opin 2010, 26:1983-1992.
13. Kaji R., Osako Y., Suyama K., Maeda T., Uechi Y., Iwasaki M. Botulinum toxin type A in post-strokelower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010, 257:1330-1337.
14. Caleo M., Antonucci F., Restani L., Mazzocchio R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?. J Neurochem 2009, 109:15-24.
15. Morenilla-Palao C., Planells-Cases R., Garcia-Sanz N., Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004, 279:25665-25672.
16. Diener H.C., Dodick D.W., Aurora S.K., Turkel C.C., DeGryse R.E., Lipton R.B., et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30:804-814.
17. Aurora S.K., Dodick D.W., Turkel C.C., DeGryse R.E., Silberstein S.D., Lipton R.B., et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30:793-803.
18. Dodick D.W., Turkel C.C., DeGryse R.E., Aurora S.K., Silberstein S.D., Lipton R.B., et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010, 50:921-936.
19. Brin M.F. Development of future indications for BOTOX. Toxicon 2009, 54:668-674.
20. Sahai A., Dowson C., Khan M.S., Dasgupta P. Repeated injections of botulinum toxin-Afor idiopathic detrusor overactivity. Urology 2010, 75:552-558.
21. Campbell J.D., Gries K.S., Watanabe J.H., Ravelo A., Dmochowski R.R., Sullivan S.D. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol 2009, 9:18.
22. Antonucci F., Bozzi Y., Caleo M. Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy. Epilepsia 2009, 50:963-966.
23. Kang J.S., Krakow K., Roggendorf J., Steinmetz H., Hilker R. Botulinum toxin treatment of epilepsia partialis continua. Mov Disord 2009, 24:141-143.